Blog - QualityStocks

FridayJun 26, 2026 3:01 pm

QualityStocksNewsBreaks – CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Focuses on Long-Term Opportunity as Market Dynamics Evolve

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising. CMX (CSE: CXC) (OTC: CXXMF) is an exploration-stage company advancing the wholly owned Clayton Silver Project in Idaho. The company was featured in a recent article that discussed its positioning to navigate increasing volatility in precious metals markets driven in part by the growing influence of derivatives trading. While derivatives can improve liquidity and provide hedging opportunities, they can also contribute to heightened leverage and skewed prices. Against this backdrop, the company remains focused on advancing its historic Clayton Silver Mine, which it believes could…

FridayJun 26, 2026 2:16 pm

QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company was featured in a recent article that discussed its efforts to broaden the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. “The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice…

FridayJun 26, 2026 12:00 pm

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings…

FridayJun 26, 2026 11:47 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification

BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with anti-doping standards established by the World Anti-Doping Agency and the UFC. Combined with the previously certified MyndMed(TM) daytime formula, the company said MyndSystem(TM) is now a fully WADA-compliant 24/7 cognitive performance and recovery system for professional athletes. The company said the certification strengthens its position in the sports nutrition market by supporting potential adoption among professional athletes while also targeting executives and active seniors. BioAdaptives said the milestone could enhance commercialization opportunities, strategic partnerships and broader market adoption as it expands the MyndSystem(TM) platform. To view the full press release, visit https://ibn.fm/LiDRP About BioAdaptives, Inc. BioAdaptives,…

FridayJun 26, 2026 11:39 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in NetworkNewsAudio Editorial on DNA Repair Therapies

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's approach to next-generation DNA repair therapies for cancer. The audio feature, titled "Next-Generation DNA Repair Therapies Open New Frontiers in Oncology," accompanies a previously published editorial examining the emerging opportunity for PNKP inhibitors within the expanding DNA Damage Response ("DDR") oncology market. The feature highlights Onco-Innovations' exclusive global rights to a portfolio of PNKP inhibitor technology, including core inhibitor molecules, nanoparticle drug delivery technology and synthetic lethality applications designed to target cancer cells. The company said this combination of molecular, delivery…

FridayJun 26, 2026 11:15 am

From Ownership to Utility: How Digital Assets Are Becoming Productive Capital

APUS is aligning its treasury strategy with the shift from Bitcoin ownership to Bitcoin productivity via yield and digital credit markets MindWave is focused on institutional-grade custody, treasury optimization and compliant digital asset infrastructure The updates highlight MindWave’s broader mission: to enable institutions to transform Bitcoin from a passive reserve asset into productive, yield-generating capital The digital asset industry is entering a new phase of development. While early blockchain adoption was largely driven by speculation and asset appreciation, today's market is increasingly focused on building sustainable financial infrastructure capable of supporting long-term institutional participation. Companies that can facilitate this transition…

FridayJun 26, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions. The milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection,…

FridayJun 26, 2026 10:15 am

QualityStocksNewsBreaks – Suntex Enterprises Inc. (OTC: SNTX) Highlights Recent Operational and Strategic Milestones

Suntex Enterprises (OTC: SNTX) announced the completion of several strategic initiatives over the past two weeks, including fulfilling commitments under its asset purchase agreement with Golden Triangle Ventures, engaging a PCAOB-registered accounting firm to begin the audit process, appointing independent director Lisa Surnow and advancing plans to qualify for the OTCQB(R) Venture Market, subject to meeting applicable listing and regulatory requirements. The company also reported continued progress on its 100-acre mixed-use South Texas development and expansion of its commercial construction business through subsidiary JA Development & Construction. Suntex said its construction subsidiary has begun work on an approximately $4 million…

FridayJun 26, 2026 10:05 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's novel approach to treating multiple sclerosis ("MS"). The audio feature, titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," accompanies a previously published editorial discussing the growing need for therapies that go beyond symptom management in a global MS therapeutics market projected to reach $38.62 billion by 2030. The feature highlights Quantum BioPharma's lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed…

FridayJun 26, 2026 9:58 am

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Partners to Digitally Preserve Roberto Clemente Legacy

Datavault AI (NASDAQ: DVLT) announced a partnership with 21 In Right Inc., the Clemente family entity that manages the name, image and likeness of Baseball Hall of Famer Roberto Clemente, to apply its data valuation, monetization and digital Twin technologies to preserve and expand Clemente's legacy. Under the agreement, 21 In Right will use Datavault AI's platforms to manage and protect Clemente's NIL rights, create digital Twins and archives, and develop new fan engagement initiatives in collaboration with the Roberto Clemente Foundation and other aligned organizations. The companies also plan to launch a fan activation in Philadelphia beginning in July featuring demonstrations of Datavault AI's artificial intelligence tools, Clemente-themed…

Site Search

Company Search